Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

银屑病面积及严重程度指数 医学 银屑病 银屑病性关节炎 内科学 临床终点 安慰剂 白细胞介素17 随机对照试验 塞库金单抗 胃肠病学 不利影响 皮肤病科 细胞因子 病理 替代医学
作者
Hidemi Nakagawa,Hiroaki Niiro,Kenji Ootaki
出处
期刊:Journal of Dermatological Science [Elsevier BV]
卷期号:81 (1): 44-52 被引量:151
标识
DOI:10.1016/j.jdermsci.2015.10.009
摘要

Abstract Background Brodalumab (KHK4827 or AMG 827) is a human monoclonal antibody that binds to the human interleukin (IL)-17 receptor A and blocks the biological activities of IL-17A, IL-17F, IL-17A/F, and IL-17E also known as IL-25. A 12-week phase 2 trial in the USA, Europe, and other countries showed the good efficacy of brodalumab in treating patients with moderate to severe plaque psoriasis. However, with the exception of a phase 1 study, a clinical trial of brodalumab in psoriasis has not been undertaken in Japan. Objective To evaluate the efficacy and safety of brodalumab in Japanese patients with moderate-to-severe plaque psoriasis, including psoriatic arthritis, in a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative phase 2 study, and to assess the pharmacokinetics of brodalumab. Methods Japanese patients with moderate-to-severe plaque psoriasis, including psoriatic arthritis, were randomized to receive 70 mg, 140 mg, or 210 mg of brodalumab, or placebo, injected subcutaneously at baseline and weeks 1, 2, 4, 6, 8, and 10. The primary efficacy endpoint was the percentage improvement in the Psoriasis Area and Severity Index (PASI) score from baseline to week 12. Secondary efficacy endpoints included the percentage of patients with ≥75% reduction of PASI scores (PASI 75), ≥90% (PASI 90), and 100% (PASI 100) and the percentage of patients with a static physician's global assessment (sPGA) of 0 (clear) or 1 (almost clear) at week 12. Safety was evaluated by assessing the adverse events (AE) and the patients' hematologic and laboratory values. Results At week 12, the mean percentage improvements in the PASI scores were 37.7%, 82.2%, 96.8%, and 9.4% in the 70 mg, 140 mg, 210 mg, and placebo groups, respectively, ( p Conclusion The rapid, robust efficacy of brodalumab and its favorable safety profile shown in the current study confirm previous studies conducted in Caucasian people, further warranting the use of brodalumab as a new treatment option for plaque psoriasis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
啦啦啦完成签到,获得积分10
1秒前
心系天下完成签到 ,获得积分10
1秒前
温暖砖头发布了新的文献求助10
1秒前
Anne完成签到 ,获得积分10
1秒前
Lisa完成签到 ,获得积分10
1秒前
双双完成签到,获得积分10
1秒前
DE_ld完成签到,获得积分10
1秒前
null的应助被quhayley采纳,获得10
2秒前
冷艳的火龙果完成签到,获得积分10
2秒前
wangwang完成签到,获得积分10
2秒前
呦呦发布了新的文献求助10
2秒前
3秒前
3秒前
深情安青的应助被ongkianwhww采纳,获得10
3秒前
zhangxin完成签到,获得积分10
4秒前
Ava的应助被酷酷柚子采纳,获得10
4秒前
4秒前
2361760724完成签到,获得积分10
4秒前
Iloveyou完成签到,获得积分10
4秒前
5秒前
苹果誉完成签到,获得积分10
5秒前
泡泡糖完成签到,获得积分10
5秒前
巳月完成签到,获得积分10
5秒前
5秒前
ly发布了新的文献求助10
5秒前
Lemonhead的应助被大大怪采纳,获得30
6秒前
lll完成签到,获得积分10
6秒前
莉莉娅完成签到 ,获得积分10
6秒前
孙七喜完成签到,获得积分10
7秒前
曦贝贝完成签到,获得积分10
7秒前
小灰灰完成签到,获得积分0
7秒前
嘟嘟完成签到,获得积分10
7秒前
panda完成签到,获得积分0
8秒前
9秒前
蜀勤完成签到,获得积分10
9秒前
研友_LJGmvn发布了新的文献求助10
9秒前
甜甜元蝶的应助被suiyi采纳,获得10
9秒前
孤独丹秋完成签到,获得积分10
10秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173474
求助须知:如何正确求助?哪些是违规求助? 9565719
关于积分的说明 21781727
捐赠科研通 7767700
什么是DOI,文献DOI怎么找? 3431597
关于科研通互助平台的介绍 2555855
邀请新用户注册赠送积分活动 2476832